Highly constrained cyclic (S,S) -CXaaC- peptides as inhibitors of fibrinogen binding to platelets

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2324-2330

  Kouki, A ^a   Mitsios, J V ^a   Sakarellos Daitsiotis, M ^a   Sakarellos, C ^a   Tselepis, A D ^a   Tsikaris, V ^a   Tsoukatos, Demokritos C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Antiaggregatory agents; Fibrinogen binding inhibitors; Integrin IIb 3 inhibitors; Platelet activation inhibitors

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CYCLOPEPTIDE; FIBRINOGEN; PADGEM PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONFORMATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

AMINO ACID SEQUENCE; BLOOD PLATELETS; FIBRINOGEN; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; P-SELECTIN; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN-TYROSINE-PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28444464009     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01487.x     Document Type: Article

References (43)

1. Philips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
2. Ikeda Y, Handa M, Kawano I, Kamata T, Murata M, Akari Y, Anbo HY, Kawai Y, Watanabe K, Itagaki I, Sakal K, Rugeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
3. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467-71.
4. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-8.
5. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559-62.
6. Pierschbacher MD, Ruoslahti E, Sundelin J, Lind P, Peterson PA. The cell attachment domain of fibronectin. Determination of the primary structure. J Biol Chem 1982; 257: 9593-7.
7. Kloczewiak M, Timmons S, Hawiger J. Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun 1982; 107: 181-7.
8. Ojima I, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg Med Chem 1995; 3: 337-60.
9. Craig WS, Cheng S, Mullen DG, Blevitt J, Pierschbacher MD. Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers 1995; 37: 157-75.
10. Stavrakoudis A, Bizos G, Eleftheriadis D, Kouki A, Panou-Pomonis E, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tsikaris V. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis and structure-function relationships. Biopolymers 2001; 56: 20-6.
11. Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists from bench to practice. Cell Mol Life Sci 2002; 59: 478-500.
12. 3 integrin antagonists. J Pharmacol Exp Ther 2001; 296: 690-6.
13. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
14. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437-44.
15. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000; 102: e76-80.
16. 1 integrins. J Biol Chem 1994; 269: 20233-8.
17. 3 antagonists. J Am Chem Soc 1996; 118: 7461-72.
18. McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S. Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 1998; 219: 109-19.
19. D'Souza SE, Ginsberg MH, Lam SC-T, Plow EF. Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets. J Biol Chem 1988; 263: 3943-51.
20. Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B. Identification of low molecular weight GPIIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther 1998; 285: 1317-26.
21. Bach AC, Eyermann CJ, Gross JD, Bower MJ, Harlow RL, Weber PC, DeGrado WF. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J Am Chem Soc 1994; 116: 3207-19.
22. Bach AC, Espina JR, Jackson SA, Stouten PFW, Duke JL, Mousa SA, DeGrado WF. Type II′ to type Iβ-turn swap changes specificity for integrins. J Am Chem Soc 1996; 118: 293-4.
23. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40: 2373-8.
24. 3 integrin antagonists. J Med Chem 1999; 42: 3033-40.
25. 2 peptide as a probe of slow conformational exchange of short linear peptides in DMSO. Biopolymers 2003; 69: 72-86.
26. Kostidis S, Stavrakoudis A, Biris N, Tsoukatos D, Sakarellos C, Tsikaris V. The relative orientation of the Arg and Asp side chains defined by a pseudo-dihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides. J Pept Sci 2004; 10: 494-509.
27. Stewart JM, Young JD. Principles of Peptide Synthesis, 2nd edn. Rockford, IL, USA: Pierce Chemical Co, 1984.
28. Atherton E, Sheppard RC. Solid Phase Peptide Synthesis: A Practical Approach. Oxford, England: IRL Press, 1989.
29. Bodansky M, Bodansky A. The Practice of Peptide Synthesis, 2nd edn. Berlin, Germany: Springer, 1994.
30. Goudevenos J, Tselepis AD, Vini MP, Michalis L, Tsoukatos DC, Elisaf M, Ninio E, Sideris DA. Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty. Eur J Clin Invest 2001; 31: 15-23.
31. 3. Eur J Biochem 2004; 271: 855-62.
32. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93: 204-14.
33. Frojmovic MM, Wong T, Van de Ven T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometer: I. Methodology, theory and results for two distinct activators. Biophys J 1991; 59: 815-27.
34. Xia Z, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear fluid: effect of shear and fibrinogen occupancy. Biophys J 1994; 66: 2190-201.
35. Frojmovic MM, Mooney RM, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding: I. Quantal activation of platelet subpopulations varies with adenosine diphosphate concentration. Biophys J 1994; 67: 2060-8.
36. Golden A, Brugge JS, Shattil SJ. Role of platelet membrane glycoprotein IIb-IIIa is an agonist-induced tyrosine phosphorylation of platelet proteins. J Cell Biol 1990; 111: 3117-27.
37. 3. Eur J Biochem 2003; 270: 3760-7.
38. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
39. 3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-5.
40. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
41. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin αIIbβ3 and ADP receptors. Blood 2002; 99: 193-8.
42. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46.
43. Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM. Effect of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets 2003; 14: 179-87.